CSL remains a buy: Tribeca

August 19, 2019

Jun Bei Liu, lead portfolio manager with Tribeca Investment Partners, talks to Livewire Markets about CSL’s strong result.

CSL has delivered a solid FY19 result with a constant currency net profit after tax of $2,015m, up 11% vs the previous corresponding period.

The strong result was underpinned by the group’s core immune globulin franchise with sales up 16% supported by both strong volumes (reflecting market share gains) and higher prices. The lift in average prices reflected higher European prices and a positive mix benefit as higher priced subcutaneous IG products grew more rapidly.

To read the full article, click here.


Categories: Insights



© GSFM 2019